Altimmune, Inc.
For the period ended Dec 31, 2025. Filed Mar 6, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 6, 2026
ALT$1.94-8.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
6. Accrued Expenses and Other Current Liabilities
- Accrued Expenses and Other Current Liabilities
Accrued expense and other current liabilities consist of the following (in thousands):
| · · · · · | |||
|---|---|---|---|
| | December 31, | ||
| | 2025 | | 2024 |
| Accrued professional services | $923 | | $401 |
| Accrued payroll and employee benefits | 4,676 | | 3,079 |
| Accrued research and development | 6,110 | | 6,443 |
| Lease obligation, current portion | 256 | | 279 |
| Accrued interest and other | 315 | | 55 |
| Total accrued expenses and other current liabilities | $12,280 | | $10,257 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.